1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Real-time Estimate Cboe Europe  -  07:35 2022-08-10 am EDT
317.38 CHF   -0.31%
05:40aROCHE HOLDINGS AG : Goldman Sachs reaffirms its Buy rating
MD
05:00aRoche's Rare Blood Disease Drug Wins Priority Review Tag In China
MT
08/09Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litigation in the U.S.
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche Launches VENTANA DP 600 slide scanner for Digital Pathology, Enhancing Patient Care with Precision Diagnostics

06/28/2022 | 01:00am EDT

Roche announced the CE launch of the next-generation VENTANA DP 600 slide scanner (CE-IVD marked). This high-capacity slide scanner produces excellent image quality of stained histology slides from patient tissue samples, while providing ease-of-use and workflow flexibility for the pathology lab. The VENTANA DP 600 slide scanner is an important addition to the Roche Digital Pathology portfolio, which provides innovative, high-quality digital solutions that automate tissue diagnostics and empower pathologists to provide faster and more comprehensive diagnostic results to healthcare providers and their patients. Digital Pathology refers to the digitalisation of the traditional pathology workflow starting from slide scanning to visualisation to analysis. Digital Pathology is transforming traditional histopathology by improving efficiency, depth of analysis, and opportunity for collaboration in pathology workflows. For example, once the slide scanner captures and converts stained tissue on glass slides to digital images, these images can be managed, shared, and analysed by pathologists and can help determine a cancer patient's treatment. This new 240-slide scanner, which builds on the success of the 6-slide VENTANA DP 200 scanner, will help anatomic pathology laboratories accelerate the digitalisation of their pathology workflow. Both scanners feature the same innovative optics and dynamic focus technology for high-resolution, high-quality colour images that accurately reproduce the image quality that pathologists see under microscopes.


© S&P Capital IQ 2022
All news about ROCHE HOLDING AG
05:40aROCHE HOLDINGS AG : Goldman Sachs reaffirms its Buy rating
MD
05:00aRoche's Rare Blood Disease Drug Wins Priority Review Tag In China
MT
08/09Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig..
AQ
08/08Chugai Pharmaceutical Co., Ltd. - Maruho Launched in Japan the Anti-IL-31 Receptor a Hu..
AQ
08/08Roche's Chugai Unit Launches Skin Disease Drug in Japan
MT
08/07Amgen says Lumakras plus immunotherapy for lung cancer needs further study
RE
08/03Poseida Therapeutics Shares Soar After Roche Collaboration
DJ
08/03Roche Signs Partnership Deal with Poseida On Hematologic Therapies
MT
08/03Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on All..
CI
08/03Poseida Therapeutics Inks Collaboration With Roche
DJ
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 64 190 M 67 344 M 67 344 M
Net income 2022 14 826 M 15 554 M 15 554 M
Net Debt 2022 10 272 M 10 776 M 10 776 M
P/E ratio 2022 17,1x
Yield 2022 3,03%
Capitalization 263 B 276 B 276 B
EV / Sales 2022 4,26x
EV / Sales 2023 4,13x
Nbr of Employees 100 920
Free-Float 82,4%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 318,35 CHF
Average target price 374,13 CHF
Spread / Average Target 17,5%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-16.02%275 991
JOHNSON & JOHNSON-0.52%447 434
ELI LILLY AND COMPANY9.70%287 922
PFIZER, INC.-16.05%279 310
ABBVIE INC.3.58%247 976
NOVO NORDISK A/S4.27%238 658